Advanced Cell Technology has issued a statement saying that the New York Times has reviewed a report in the journal Nature surrounding the firm's approach to generating human embryonic stem cells without destroying the embryo, stating: "the Journal affirmed the report's scientific validity."
The technique, ACT explains, is modeled on pre-implantation genetic diagnosis, an approach for single-cell biopsy using micromanipulation that does not interfere with the developmental capacity of the parent embryo. The Nature paper appeared in the November 23 print issue, but was first published on-line in August.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze